Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RESP 301

Next Previous
Drug Profile

RESP 301

Alternative Names: RESP 30 TB; RESP-301

Latest Information Update: 31 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Thirty respiratory
  • Class Anti-infectives; Antivirals
  • Mechanism of Action Membrane fusion protein inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis
  • No development reported Respiratory tract infections

Most Recent Events

  • 18 Jul 2025 Thirty Respiratory plans a phase II trial for Pulmonary tuberculosis (Newly diagnosed) in South Africa (Inhalation) (NCT07073638)
  • 15 Jul 2025 Thirty Respiratory terminates a phase II trial in Tuberculosis (Treatment-naive) in South Africa (Inhalation), as the decision was made by the sponsor not to progress to Stage 2 (NCT06041919)
  • 18 Dec 2023 Thirty Respiratory terminates a phase II/III trial in COVID 2019 infetcion in the UK due to dynamic nature of the COVID-19 pandemic and a very sharp decline in the COVID-19 patients post vaccination (NCT04842331)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top